Roche and Spark Therapeutics, Inc. announce expected refiling date of Premerger Notification and Report Forms under the HSR Act and extension of tender offer for shares of Spark Therapeutics, Inc.

Roche and Spark Therapeutics, Inc. ( “Spark”) today announced that Roche and Spark intend to refile on or about 23 May 2019 their respective Premerger Notification and Report Forms under the Hart-Scott-Rodino Act (the “HSR Act”) in connection with Roche’s pending acquisition of Spark pursuant to its previously announced tende r offer to purchase all of the outstanding shares of common stock (the “Shares”) of Spark for USD 114.50 per Share, net to the seller thereof in cash, without interest and subject to any withholding taxes required by applicable law and upon the terms and subject to the conditions set forth in th e Offer to Purchase dated 7 March 2019 (as it may be amended and supplemented from time to time, the “Offer”).
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news